Hoth Therapeutics Inc (HOTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hoth Therapeutics Inc (HOTH) has a cash flow conversion efficiency ratio of -0.303x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.49 Million) by net assets ($8.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hoth Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Hoth Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read HOTH total liabilities for a breakdown of total debt and financial obligations.
Hoth Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hoth Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nature and Environment Co. Ltd
KQ:043910
|
-0.021x |
|
Connexion Mobility Ltd
AU:CXZ
|
0.113x |
|
Dromeas SA
AT:DROME
|
0.020x |
|
Multi Prima Sejahtera Tbk
JK:LPIN
|
-0.008x |
|
Great Northern Minerals Ltd
AU:GNM
|
-0.073x |
|
Barnwell Industries Inc
NYSE MKT:BRN
|
-0.216x |
|
Zacatecas Silver Corp
V:ZAC
|
-0.018x |
|
ECP Emerging Growth Ltd
AU:ECP
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Hoth Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Hoth Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see HOTH market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.88 Million | $-6.98 Million | -1.014x | -14.55% |
| 2023-12-31 | $9.54 Million | $-8.45 Million | -0.886x | +51.22% |
| 2022-12-31 | $5.12 Million | $-9.30 Million | -1.815x | -48.39% |
| 2021-12-31 | $9.88 Million | $-12.09 Million | -1.223x | +7.33% |
| 2020-12-31 | $4.65 Million | $-6.13 Million | -1.320x | +36.06% |
| 2019-12-31 | $2.40 Million | $-4.95 Million | -2.065x | +84.78% |
| 2018-12-31 | $154.97K | $-2.10 Million | -13.568x | -3354.39% |
| 2017-12-31 | $1.18 Million | $-465.24K | -0.393x | -- |
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell deriv… Read more